Kim D. Blickenstaff - 17 May 2022 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role
Director
Signature
s/ Rachel Malina, Attorney-in-Fact for Kim D. Blickenstaff
Issuer symbol
TNDM
Transactions as of
17 May 2022
Net transactions value
+$1,117,927
Form type
4
Filing time
19 May 2022, 19:14:19 UTC
Previous filing
28 Jun 2022
Next filing
27 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNDM Common Stock Options Exercise $59,040 +6,560 +347% $9.00 8,452 17 May 2022 Direct F1
transaction TNDM Common Stock Options Exercise $0 +2,205 +26% $0.000000 10,657 18 May 2022 Direct
transaction TNDM Common Stock Options Exercise $999,872 +13,562 +6.7% $73.73 215,952 17 May 2022 See Footnote F2, F3
transaction TNDM Common Stock Sale $999,897 -10,762 -5% $92.91 205,190 17 May 2022 See Footnote F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNDM Stock Option Options Exercise $59,040 +6,560 $9.00 0 17 May 2022 Common Stock 6,560 $9.00 Direct F4, F5
transaction TNDM Warrant Options Exercise $999,872 +13,562 $73.73 0 17 May 2022 Common Stock 13,562 $73.73 See Footnote F3, F6
transaction TNDM Restricted Stock Unit Options Exercise $0 +2,205 $0.000000* 0 18 May 2022 Common Stock 2,205 Direct F7, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon exercise of a stock option award.
F2 The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer.
F3 The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010.
F4 The options vested as to twenty-five percent (25%) of the underlying shares on 5/17/2018, and the remaining shares vested in thirty-six (36) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the 2013 Plan).
F5 The expiration date for these options is 10 years from the date of grant.
F6 The expiration dates for these warrants are May 25, 2022 (2,712 shares), and July 3, 2022 (10,850 shares).
F7 Awarded on May 18, 2021 pursuant to the 2013 Plan, as amended, and the agreements related thereto.
F8 Each restricted stock (RSU) unit represents a contingent right to receive one share of common stock of the Company.
F9 Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan.